Spiriva Respimat 2,5 mikrogram inhalationsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

spiriva respimat 2,5 mikrogram inhalationsvæske, opløsning

paranova danmark a/s - tiotropium bromid - inhalationsvæske, opløsning - 2,5 mikrogram

Ventoline 1 mg/ml inhalationsvæske til nebulisator, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ventoline 1 mg/ml inhalationsvæske til nebulisator, opløsning

glaxosmithkline pharma a/s - salbutamolsulfat - inhalationsvæske til nebulisator, opløsning - 1 mg/ml

Ventoline 5 mg/ml inhalationsvæske til nebulisator, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ventoline 5 mg/ml inhalationsvæske til nebulisator, opløsning

glaxosmithkline pharma a/s - salbutamolsulfat - inhalationsvæske til nebulisator, opløsning - 5 mg/ml

Bumacor 20 mg/ml injektionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

bumacor 20 mg/ml injektionsvæske, opløsning

macure pharma aps - hyoscinbutylbromid - injektionsvæske, opløsning - 20 mg/ml

Airexar Spiromax Den Europæiske Union - dansk - EMA (European Medicines Agency)

airexar spiromax

teva b.v. - salmeterol, fluticasonpropionat - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - airexar spiromax er indiceret til brug kun hos voksne i alderen 18 år og ældre. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. kronisk obstruktiv lungesygdom (kol)airexar spiromax er indiceret til symptomatisk behandling af patienter med kol med fev1.

BiResp Spiromax Den Europæiske Union - dansk - EMA (European Medicines Agency)

biresp spiromax

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).